Bert L. Lum

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

Roy S. Herbst, S. Gail Eckhardt, Razelle Kurzrock et al. · Journal of Clinical Oncology · 2010 · 437 citations

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

Jianfeng Lü, René Bruno, Steve Eppler et al. · Cancer Chemotherapy and Pharmacology · 2008 · 343 citations

Oncology, Medicine, Pharmacotherapy +3

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

Gustavo Ismael, Roberto Hegg, Susanne Muehlbauer et al. · The Lancet Oncology · 2012 · 337 citations

Hannah Study, Breast Oncology, Oncology +6

Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)

Peter L. Greenberg, Sandra J. Lee, Ranjana H. Advani et al. · Journal of Clinical Oncology · 2004 · 232 citations · Full text

METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS

Jie Ling, Kim A. Johnson, Zhuang Miao et al. · Drug Metabolism and Disposition · 2005 · 219 citations